Peptides and Metabolic Research: How Science Approaches Fat Metabolism
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
- This is an overview of how scientists study peptides in fat metabolism and blood-sugar control, centered on the GLP-1 family such as semaglutide and tirzepatide.
- The strongest evidence is for the approved GLP-1 medicines, which large human trials link to weight and blood-sugar changes; those findings come from the trials, not from BioRegen.
- Newer and experimental compounds in this space have much thinner evidence, and online discussion about them is unverified personal anecdote.
- Nothing here is a treatment claim, and none of BioRegen's materials are approved for human or veterinary use.
- BioRegen sells these strictly for laboratory and educational research.
Studying how the body burns and stores fat is one of the busiest areas of peptide science. "Metabolism" just means how the body turns food into energy and decides what to do with it. This page walks through how scientists study certain peptides in that setting, and what the published studies have reported so far. All information is for laboratory and educational research only. These compounds are not approved for human or veterinary use, and nothing here is medical advice.
The peptides most studied in this area
A handful of peptides show up again and again in the research. They are grouped here by how many of the body's signaling "switches," called receptors, they act on. A peptide that flips a switch is called an agonist.
- Semaglutide · acts on one switch, the GLP-1 receptor. It is the most-published of the group, so scientists often use it as a baseline to compare the others against.
- Tirzepatide · acts on two switches, GLP-1 and GIP. Trials have looked at whether hitting both leads to bigger effects on how the body handles food and energy [2].
- Retatrutide · acts on three switches, GLP-1, GIP, and glucagon. It is newer and has been studied less, so the evidence is at an earlier stage [1].
- 5-Amino-1MQ, MOTS-c · studied through other routes in the body, not the same switches above.
How researchers study the way these work
A lot of this work looks at "incretin" signaling. Incretins are natural gut hormones that help the body manage blood sugar and the feeling of hunger. The GLP-1 and GIP switches mentioned above are part of that system. Other research looks at how cells make and use energy, including the work done by mitochondria, the tiny power plants inside cells. In the studies done so far, peptides that act on more switches have tended to show wider effects in lab models. Keep in mind that the amount of evidence is not the same for each one. Some have been studied a lot, others very little.
Selected research references
- [1] Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity · A Phase 2 Trial. N Engl J Med. doi:10.1056/NEJMoa2301972
- [2] Rosenstock J, et al. (2021). Efficacy and safety of tirzepatide in type 2 diabetes (SURPASS-1). Lancet. doi:10.1016/S0140-6736(21)01324-6
Reference metadata sourced via PubMed.
Browse the BURN metabolic research collection or read our retatrutide vs tirzepatide vs semaglutide comparison. Join the research list for 10% off your first order by creating a free account.
Disclaimer: All products and information provided by BioRegen are for laboratory and educational research purposes only. Nothing here is medical advice, and none of these compounds are approved for human or veterinary use.